MEDICAL POLICY – 8.01.26
Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

BCBSA Ref. Policy: 8.01.26
Effective Date: May 1, 2018
Last Revised: April 3, 2018
Replaces: N/A

RELATED MEDICAL POLICIES:
7.01.50 Placental and Umbilical Cord Blood as a Source of Stem Cells
8.01.24 Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults
8.01.30 Hematopoietic Cell Transplantation for Treatment of Chronic Myelogenous Leukemia
8.01.520 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | CODING | RELATED INFORMATION
EVIDENCE REVIEW | REFERENCES | HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

Introduction

The bone marrow is filled with cells known as hematopoietic stem cells. These immature cells develop into different types of blood cells: white blood cells to fight infection, red blood cells to carry oxygen, and platelets to clot the blood. In some cases, treating cancer also means destroying the bone marrow’s natural ability to create healthy blood cells. Restoring this function means returning these immature cells — the hematopoietic stem cells — to the body. When the immature blood cells come from a donor it’s known as an allogeneic transplant. When the cells are collected from the patient, stored, and later given back to the same patient it’s called an autologous transplant (autologous means from the same person). This policy describes when these transplants may be considered medically necessary for acute myeloid leukemia.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
### Policy Coverage Criteria

#### Treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Medical Necessity</th>
</tr>
</thead>
</table>
| **Allogeneic hematopoietic cell transplantation (HCT)** | Allogeneic hematopoietic cell transplantation (HCT) using a myeloablative conditioning regimen may be considered medically necessary to treat:  
- Poor- to intermediate-risk AML in first complete remission (CR1) (see Table 1)  
OR  
- AML that is refractory to standard induction chemotherapy but can be brought into CR with intensified induction chemotherapy  
OR  
- AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy  
OR  
- AML in patients who have relapsed following a prior autologous HCT, but can be brought into CR with intensified induction chemotherapy and are medically able to tolerate the procedure. |
| **Allogeneic HCT using a reduced-intensity conditioning regimen** | Allogeneic HCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in patients who are in complete marrow and extramedullary remission (CR1 or beyond), and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen. |
| **Autologous HCT** | Autologous HCT may be considered medically necessary to treat AML in CR1 or beyond, or relapsed AML, if responsive to intensified induction chemotherapy. |

Primary refractory acute myeloid leukemia (AML) is defined as leukemia that does not achieve a complete remission after conventionally dosed (non-marrow ablative) chemotherapy.
In the French-American-British (FAB) criteria, the classification of AML is solely based on morphology as determined by the degree of differentiation along different cell lines and the extent of cell maturation.

Clinical features that predict poor outcomes of AML therapy include, but are not limited to, the following:

- Treatment-related AML (secondary to prior chemotherapy and/or radiotherapy for another malignancy)
- AML with antecedent hematologic disease (e.g., myelodysplasia)
- Presence of circulating blasts at the time of diagnosis
- Difficulty in obtaining first complete remission with standard chemotherapy
- Leukemias with monocytoid differentiation (FAB classification M4 or M5)

The newer, currently preferred, World Health Organization (WHO) classification of AML incorporates and interrelates morphology, cytogenetics, molecular genetics, and immunologic markers in an attempt to construct a classification that is universally applicable and prognostically valid. The WHO system was adapted by NCCN to estimate individual patient prognosis to guide management, as shown in Table 1.

Table 1. Risk Status of AML Based on Cytogenetic and Molecular Factors

<table>
<thead>
<tr>
<th>Risk Status</th>
<th>Cytogenetic Factors</th>
<th>Molecular Abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable</td>
<td>Inv(16), t(8;21), t(16;16)</td>
<td>Normal cytogenetics with isolated NPM1 variant</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Normal +8 only, t(9;11) only Other abnormalities not listed with better-risk and poor-risk cytogenetics</td>
<td>c-KIT variant in patients with t(8;21) or inv(16)</td>
</tr>
<tr>
<td>Poor</td>
<td>Complex (3 or more abnormalities) -5, -7, 5q-, 7q-, +8, Inv3, t(3;3), t(6;9), t(9;22) Abnormalities of 11q23, excluding t(9;11)</td>
<td>Normal cytogenetics with isolated FLT3-ITD variant</td>
</tr>
</tbody>
</table>

AML: acute myeloid leukemia; ITD: internal tandem duplication.
## Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPT</strong></td>
<td></td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
<tr>
<td>38240</td>
<td>Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor</td>
</tr>
<tr>
<td>38241</td>
<td>Hematopoietic progenitor cell (HPC); autologous transplantation</td>
</tr>
<tr>
<td>38242</td>
<td>Allogeneic donor lymphocyte infusions</td>
</tr>
<tr>
<td><strong>HCPCS</strong></td>
<td></td>
</tr>
<tr>
<td>S2140</td>
<td>Cord blood harvesting for transplantation, allogeneic</td>
</tr>
<tr>
<td>S2142</td>
<td>Cord blood derived stem cell transplantation, allogeneic</td>
</tr>
<tr>
<td>S2150</td>
<td>Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition</td>
</tr>
</tbody>
</table>

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information

The relative importance of cytogenetic and molecular abnormalities in determining prognosis and guiding therapy is under investigation.

The ideal allogeneic donors are HLA-identical siblings, matched at the HLA-A, -B, and DR loci (6 of 6). Related donors mismatched at one locus are also considered suitable donors. A matched, unrelated donor identified through the National Marrow Donor Registry is typically the next option considered. Recently, there has been interest in haploidentical donors, typically a parent or a child of the patient, for which there usually is sharing of only 3 of the 6 major histocompatibility antigens. Most patients will have such a donor; however, the risk of graft-
Evidence Review

Description

Acute myeloid leukemia (AML) refers to leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into various postremission strategies using either allogeneic (allo-) or autologous hematopoietic cell transplantation (HCT). HCT refers to a procedure that infuses hematopoietic stem cells to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of drugs with or without whole body radiotherapy.

Background

Acute Myeloid Leukemia

Acute myeloid leukemia (AML), also called acute nonlymphocytic leukemia, AML refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. AML is characterized by proliferation of myeloblasts, coupled with low production of mature red blood cells, platelets, and often non-lymphocytic white blood cells (granulocytes, monocytes). Clinical signs and symptoms are associated with neutropenia, thrombocytopenia, and anemia. The incidence of AML increases with age, with a median of 67 years. Approximately 21,380 new cases are diagnosed annually.¹

Pathophysiology

The pathogenesis of AML is unclear. It can be subdivided according to resemblance to different subtypes of normal myeloid precursors using the FAB classification. This system classifies leukemias from M0–M7, based on morphology and cytochemical staining, with immunophenotypic data in some instances. The World Health Organization (WHO) subsequently incorporated clinical, immunophenotypic, and a wide variety of cytogenetic abnormalities that

versus-host disease (GVHD) and overall morbidity of the procedure may be severe, and experience with these donors is not as extensive as that with matched donors.
occur in 50% to 60% of AML cases into a classification system that can be used to guide treatment according to prognostic risk categories.

**Classification**

The WHO system recognizes five major subcategories of AML:

1. AML with recurrent genetic abnormalities;
2. AML with multilineage dysplasia;
3. Therapy-related AML and myelodysplasia;
4. AML not otherwise categorized.
5. Acute leukemia of ambiguous lineage.

AML with recurrent genetic abnormalities includes AML with t(8;21)(q22;q22), inv(16)(p13;q22) or t(16;16)(p13;q22), t(15;17)(q22;q12), or translocations or structural abnormalities involving 11q23. Younger patients may exhibit t(8;21) and inv(16) or t(16;16). AML patients with 11q23 translocations include two subgroups: AML in infants and therapy-related leukemia.

Multilineage dysplasia AML must exhibit dysplasia in 50% or more of the cells of two lineages or more. It is associated with cytogenetic findings that include -7/del(7q), -5/del(5q), +8, +9, +11, del(11q), del(12p), -18, +19, del(20q)+21, and other translocations. AML not otherwise categorized includes disease that does not fulfill criteria for the other groups and essentially reflects the morphologic and cytochemical features and maturation level criteria used in the FAB classification, except for the definition of AML as having a minimum of 20% (as opposed to 30%) blasts in the marrow. AML of ambiguous lineage is diagnosed when blasts lack sufficient lineage-specific antigen expression to classify as myeloid or lymphoid.

**Hematopoietic Cell Transplantation**

Hematopoietic cell transplantation (HCT) may use stem cells obtained from the transplant recipient (autologous HCT) or from a related or unrelated donor (allogeneic HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in greater detail in a separate policy (see Related Policies).
Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT; however, immunologic compatibility between donor and patient is critical for achieving a good outcome with allo-HCT. Immunologic compatibility is established by classifying human leukocyte antigens (HLAs) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (with the exception of umbilical cord blood).

**Conventional Conditioning for HCT**

The conventional practice of allo-HCT involves administration of cytotoxic agents (eg, cyclophosphamide, busulfan) with or without total body irradiation; this is performed at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect of this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that is mediated by non-self-immunologic effector cells that develop after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are medically fit to tolerate substantial adverse events that include preengraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HCT, immunosuppressant drugs are required to minimize graft rejection and GVHD, which also increase susceptibility to opportunistic infections. The immune reactivity between donor T-cells and malignant cells is responsible for the GVM effect; it also leads to acute and chronic GVHD.

The success of autologous HCT is predicated on the ability of cytotoxic chemotherapy (with or without radiation) to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. As a consequence, autologous HCT is typically performed when the patient’s disease is in complete remission. Patients who undergo autologous HCT are susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.
**Reduced-Intensity Conditioning for Allo-HCT**

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is 2-fold: to reduce disease burden, and to minimize treatment-related morbidity and nonrelapse mortality in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of nonrelapse mortality and relapse due to residual disease. RIC regimens can be viewed as a continuum—from nearly totally myeloablative to minimally myeloablative with lymphoablation—because it tailors its intensity to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For this evidence review, RIC refers to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

**Genetic Abnormalities**

Molecular studies have identified a number of genetic abnormalities that also can be used to guide prognosis and management of AML. Cytogenetically normal AML is the largest defined subgroup of AML, comprising approximately 45% of all AML cases. Despite the absence of cytogenetic abnormalities, these cases often have genetic variants that affect outcomes, six of which have been identified. The FLT3 gene that encodes FMS-like receptor tyrosine kinase 3, a growth factor active in hematopoiesis, is mutated in 33% to 49% of cytogenetically normal AML cases; among those, 28% to 33% consist of internal tandem duplications, 5% to 14% are missense variants in exon 20 of the tyrosine kinase activation loop, and the rest are single nucleotide variants (SNVs) in the juxtamembrane domain. All FLT3 variants result in a constitutively activated protein and confer a poor prognosis. Several pharmaceutic agents that inhibit the FLT3 tyrosine kinase are under investigation.

**Treatment**

Complete remission can be achieved initially using induction therapy, consisting of conventional doses of combination chemotherapy. A complete response is achieved in 60% to 80% of adults younger than 60 years of age and in 40% to 60% in patients older than 60 years of age.
However, the high incidence of disease relapse has prompted research into a variety of postremission (consolidation) strategies, typically using high-dose chemotherapy with autologous hematopoietic cell transplantation (HCT) or high-dose or reduced-intensity chemotherapy with allogeneic HCT (allo-HCT). The 2 treatments—autologous HCT and allo-HCT—represent 2 different strategies. The first, autologous HCT, is a “rescue,” but not a therapeutic procedure; the second, allo-HCT, is a “rescue” plus a therapeutic procedure.

**Hematopoietic Cell Transplantation**

HCT is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of drugs with or without whole-body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allo-HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in detail in a separate policy (see Related Policies).

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT; however, immunologic compatibility between donor and patient is critical for achieving a good outcome with allo-HCT. Immunologic compatibility is established by classifying human leukocyte antigens (HLAs) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci (with the exception of umbilical cord blood).

**Conventional Conditioning for HCT**

The conventional practice of allo-HCT involves administration of cytotoxic agents (eg, cyclophosphamide, busulfan) with or without total body irradiation; this is performed at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect of this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that is mediated by non-self-immunologic effector cells that develop after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are medically...
fit to tolerate substantial adverse events that include preengraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HCT, immunosuppressant drugs are required to minimize graft rejection and GVHD, which also increase susceptibility to opportunistic infections. The immune reactivity between donor T cells and malignant cells is responsible for the GVM effect; it also leads to acute and chronic GVHD.

The success of autologous HCT is predicated on the ability of cytotoxic chemotherapy (with or without radiation) to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. As a consequence, autologous HCT is typically performed when the patient’s disease is in complete remission. Patients who undergo autologous HCT are susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

**Reduced-Intensity Conditioning for Allo-HCT**

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is 2-fold: to reduce disease burden, and to minimize treatment-related morbidity and nonrelapse mortality when the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of nonrelapse mortality and relapse due to residual disease. RIC regimens can be viewed as a continuum—from nearly totally myeloablative to minimally myeloablative with lymphoablation—because it tailors its intensity to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For this evidence review, RIC refers to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

A 2015 review in the *New England Journal of Medicine* has summarized recent advances in the classification of AML, the genomics of AML and prognostic factors, and current and new treatments.²
Summary of Evidence

For individuals who have cytogenetic or molecular intermediate- or poor-risk acute myeloid leukemia (AML) in first complete remission who receive allogeneic hematopoietic cell transplantation (allo-HCT) with myeloablative conditioning, the evidence includes randomized controlled trials (RCTs) and matched cohort studies. Relevant outcomes are overall survival (OS) and disease-specific survival. The evidence has revealed that allo-HCT is better at improving overall and disease-specific survival rates in patients with AML in first complete remission than conventional chemotherapy. All trials employed natural randomization based on donor availability and an intention-to-treat analysis. Survival rates appear to be associated with presence of minimal residual disease and risk category. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML refractory to standard induction chemotherapy who receive allo-HCT with myeloablative conditioning, the evidence includes retrospective data compiled from patients entered in phase 3 trials and registry data. Relevant outcomes are OS and disease-specific survival. The evidence would suggest that allo-HCT improves overall and disease-specific survival rates in patients with refractory AML better than conventional chemotherapy. While there are some limitations to the evidence, which include its retrospective nature, lack of rigorous randomization, and general pitfalls of registry data, these results may provide clinically meaningful benefit for such patients who do not have other treatment options. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML who relapsed after standard induction chemotherapy-induced first complete remission who receive allo-HCT or autologous HCT with myeloablative conditioning, the evidence includes retrospective data compiled from patients entered in phase 3 trials and registry data. Relevant outcomes are OS and disease-specific survival. The evidence has shown that allo-HCT improves OS rates in patients with relapsed AML better than conventional chemotherapy. Limitations of the evidence include its retrospective nature, lack of rigorous randomization, and pitfalls of registry data. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have cytogenetic or molecular intermediate- or poor-risk AML in first complete remission and for medical reasons cannot tolerate myeloablative conditioning who receive allo-HCT with reduced-intensity conditioning, the evidence includes 2 RCTs and other comparative and noncomparative studies. Relevant outcomes are OS, disease-specific survival, and treatment-related morbidity. The RCTs compared reduced-intensity conditioning with myeloablative conditioning and reported similar rates in nonrelapse mortality, relapse, and OS.
though one of the trials was stopped prematurely due to a slow accrual of patients. Two retrospective comparative studies found no difference in OS or leukemia-free survival between the conditioning regimens. It appears unlikely that additional comparative evidence is likely be generated. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML in first complete remission or beyond without a suitable allo-HCT donor who receive autologous HCT, the evidence includes prospective cohort studies in which patients with an available sibling donor were offered allo-HCT (biologic randomization) with random assignment of all others to autologous HCT or chemotherapy (or no further treatment); and randomized trials comparing autologous HCT with chemotherapy in all patients. Relevant outcomes are OS and disease-specific survival. Compared with chemotherapy, patients undergoing autologous HCT experienced reduced relapse and improved disease-free survival rates. OS did not differ between the groups. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 2.

**Table 2. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00342316</td>
<td>Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation with Reduced Conditioning versus Best Standard Care in Acute Myeloid Leukemia in First Complete Remission</td>
<td>360</td>
<td>Dec 2017</td>
</tr>
<tr>
<td>NCT02626715</td>
<td>A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</td>
<td>16</td>
<td>Sep 2019</td>
</tr>
<tr>
<td>NCT02441803</td>
<td>Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients with Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy</td>
<td>75</td>
<td>Sep 2022</td>
</tr>
</tbody>
</table>
### NCT No. | Trial Name | Planned Enrollment | Completion Date
--- | --- | --- | ---
Unpublished | NCT00766779 Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT from Related and Unrelated Donors as Consolidation Therapy for Older Patients with AML in 1st Complete Remission | 231 | Dec 2018 (terminated)

NCT: national clinical trial.

### Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various Physician Specialty Societies and Academic Medical Centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the Physician Specialty Societies or Academic Medical Centers, unless otherwise noted.

In response to requests, input was received from 1 physician specialty society (2 reviewers) and 1 academic medical center while this policy was under review for February 2009. There was strong consensus among reviewers that RIC allogeneic HCT was of value in patients who were in complete remission. There was general support for the policy statements.

### Practice Guidelines and Position Statements

**The National Comprehensive Cancer Network (NCCN)**

The National Comprehensive Cancer Network clinical guidelines (v.3.2017) for acute myeloid leukemia (AML) are consistent with this review.\(^{48}\) The Network guidelines state that HCT in the context of a clinical trial or best supportive care is recommended for patients with induction failure. Also, a matched unrelated donor search, including umbilical cord blood, should be initiated for high-risk patients who are eligible for HCT in first complete remission or considered at first relapse in appropriate patients concomitant with reinduction therapy. Recommendations also include autologous HCT in patients who achieve second molecular remission and to reserve allogeneic transplant for those patients who have persistent disease, despite therapy for relapsed disease.
European Society for Blood and Marrow Transplantation

As part of the position statement published in 2017 on behalf of the European Society for Blood and Marrow Transplantation (EBMT, Lee et al summarized the current literature regarding allogeneic HCT (allo-HCT) in patients with AML. For patients who lack a matched related or unrelated donor, recent retrospective and registry studies have suggested that allogeneic HCT is an option using a donor who is haploidentical to the patient or in whom all but 1 or 2 human leukocyte antigen loci match that of the patient. While the EBMT did not determine a superior method for haploidentical HCT, it was noted that the preliminary evidence suggests patient outcomes similar to those observed following single or double umbilical cord blood transplantation. The review of the literature did not include pooled analyses of the results, but the EBMT advocates that more prospective studies be conducted, given the potential benefit for AML patients who do not have eligible donors under standard guidelines.

Canadian Consensus Guidelines

Brandwein et al (2017) updated evidence-based consensus guidelines from a group of Canadian leukemia experts on the appropriate induction regimens for AML patients who are older; the group considered both candidates for allo-HCT and patients ineligible for transplant. The consensus group expanded the indication for induction therapy to any patient younger than 80 years old who is eligible for HCT and who does not present with high comorbidities or adverse risk cytogenetics. As potential induction regimens for individuals with intermediate-to-favorable risk cytogenetics, the consensus group recommended the 3+7 regimen (which may include daunorubicin, idarubicin, or mitoxantrone, followed by cytarabine) or, if unable to receive anthracyclines, the FLAG regimen, which consists of fludarabine, cytarabine, and filgrastim. Midostaurin may be administered to patients younger than 70 years in whom a FLT3 internal tandem duplication or tyrosine kinase domain variant is detected; if no such variant (FLT3) is present, gemtuzumab ozogamicin may be administered. Concerning HCT, the consensus group confirmed that haploidentical donors may be selected for patients who lack a matched donor (whether a relative or unrelated); and HCT may be considered in patients younger than 75 years of age and in patients whose disease is in second complete remission.
Medicare National Coverage

The Centers for Medicare & Medicaid Services have the following national coverage determination on use of autologous cell transplantation for AML \( ^{51} \): “Acute leukemia in remission who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched.”

Regulatory Status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

References


### History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/01/00</td>
<td>Add to Therapy Section - New Policy — replaces 8.01.15, original master policy on HDC for miscellaneous malignancies. However, policy statement is unchanged.</td>
</tr>
<tr>
<td>12/21/00</td>
<td>Replace Policy - Policy statement revised to state that allogeneic transplant after a prior failed autotransplant is considered investigational, based on 2000 TEC Assessment.</td>
</tr>
<tr>
<td>05/13/03</td>
<td>Replace Policy - Policy updated, references added; no change in policy statement. Updated CPT codes.</td>
</tr>
<tr>
<td>08/12/03</td>
<td>Replace Policy - Policy reviewed and recommended for approval by OAP July 22, 2003; no change in policy statement.</td>
</tr>
<tr>
<td>12/14/04</td>
<td>Replace Policy - Policy updated with references, NCCN guidelines, and NCI clinical trials information. Policy statement unchanged.</td>
</tr>
<tr>
<td>01/10/06</td>
<td>Replace Policy - Policy updated with literature search; NCI information updated; no change to policy statement.</td>
</tr>
<tr>
<td>06/02/06</td>
<td>Disclaimer and Scope update - No other changes</td>
</tr>
<tr>
<td>06/12/07</td>
<td>Replace Policy - Policy updated with literature review; references added. No change in policy statement. Reviewed by OAP on May 24, 2007.</td>
</tr>
<tr>
<td>10/09/07</td>
<td>Cross References Updated - No other changes.</td>
</tr>
</tbody>
</table>
| 11/11/08    | Replace Policy - Policy extensively updated with literature search. Policy statement updated to remove “HDC” from statement and replaced with “cell transplantation”. This update also reflected in the title and throughout the policy. Investigational statement was added to include Allogeneic SCT to treat AML relapsing after prior relapse.
<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/15/09</td>
<td>Replace Policy - Policy extensively updated with literature search. Policy statements updated to include allogeneic HCT used in patients with poor to intermediate risk AML in remission and that allogeneic HCT may be used after failed autologous HCT. References added. Reviewed by OAP on August 20, 2009.</td>
</tr>
<tr>
<td>02/09/10</td>
<td>Code Update - New 2010 codes added.</td>
</tr>
<tr>
<td>09/14/10</td>
<td>Replace Policy - Policy updated with literature review; references 10, 21-23 added. No change in policy statements.</td>
</tr>
<tr>
<td>10/11/11</td>
<td>Replace Policy – Policy updated with literature search; reference 12 added. No change to policy statements. ICD-9 and HCPCS codes updated; ICD-10 codes added. Title changed from &quot;myelogenous&quot; to &quot;myeloid&quot; leukemia. Codes 38220 and 38221 removed from policy.</td>
</tr>
<tr>
<td>01/24/12</td>
<td>Code 38232 added.</td>
</tr>
<tr>
<td>02/10/12</td>
<td>The CPT code 38204 was removed from the policy, as it is not specific to transplant.</td>
</tr>
<tr>
<td>06/20/12</td>
<td>Minor update: Related Policies updated; 8.01.17 replaced 8.01.507 effective June 12, 2012.</td>
</tr>
<tr>
<td>07/30/12</td>
<td>Related Policies title updates: 8.01.21, 8.01.22, 8.01.29, 8.01.30, 8.01.31, 8.01.35, 8.01.514, and 8.01.520</td>
</tr>
<tr>
<td>10/14/13</td>
<td>Replace policy. Rationale updated based on a literature review through July 1, 2013. Reference 27 added; others renumbered/removed. Policy statements unchanged. Code 38204 removed; this is not reviewed.</td>
</tr>
<tr>
<td>12/06/13</td>
<td>Update Related Policies. Remove 8.01.31 as it was archived.</td>
</tr>
<tr>
<td>03/21/14</td>
<td>Update Related Policies. Remove 8.01.514 as it was deleted.</td>
</tr>
<tr>
<td>04/18/14</td>
<td>Update Related Policies. Remove 8.01.20 and add 8.01.529.</td>
</tr>
<tr>
<td>06/24/14</td>
<td>Update Related Policies. Remove 8.01.35 and 8.01.42, then add 8.01.530 and 8.01.532.</td>
</tr>
<tr>
<td>11/20/14</td>
<td>Annual Review. Policy updated with literature review through June 18, 2014; references 13, and 35-36 added. No change to policy statements. ICD-9 and ICD-10 diagnosis and procedure codes removed; they do not relate to adjudication of the policy.</td>
</tr>
<tr>
<td>11/10/15</td>
<td>Annual Review. Policy updated with literature review through July 9, 2015; no references added. Policy statements updated with clarifying information and to align with other HCT policies but the intent remains unchanged.</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>05/01/16</td>
<td>Annual Review, approved April 12, 2016. Policy updated with literature review through December 13, 2015; references 2-3 and 35 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>11/04/16</td>
<td>Coding update. Removed codes that are transplant benefit related.</td>
</tr>
<tr>
<td>06/09/17</td>
<td>Coding update. Updated description for CPT codes 38240 and 38241.</td>
</tr>
<tr>
<td>05/01/18</td>
<td>Annual Review, approved April 3, 2018. Policy updated with literature review through November 2017; references 16-17 and 49-51 added. Policy statements unchanged.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination Is Against the Law

LifeWise Health Plan of Oregon complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

LifeWise:
• Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  • Qualified sign language interpreters
  • Written information in other formats (large print, audio, accessible electronic formats, other formats)
• Provides free language services to people whose primary language is not English, such as:
  • Qualified interpreters
  • Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-6396, Fax 425-918-5592. TTY 800-842-5357
Email AppealsDepartmentInquiries@LifeWiseHealth.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services,
Office for Civil Rights
200 Independence Avenue SW, Room 509F, HHT Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through LifeWise Health Plan of Oregon. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-596-3440 (TTY: 800-842-5357).

Arabic:
لا يجوز تجاهل هذه المعلومات. إذا كنت تلقيت هذه المعلومة على لغتك العربية، فعليك العمل وفقًا لها. إذا كنت غير قادر على اللغة العربية، فلديك الحق في الحصول على مساعدة باللغة العربية.

Chinese (Chinese):
本通知有重要的讯息。本通知可能有关於您透過 LifeWise Health Plan of Oregon 提交的申請或保單的重要訊息。本通知內可能有重要日期。您可能需要在截止日期之前採取行動。以保留您的健康保險或費用補貼。您有權利免費以您的母語得到本訊息和協助。請撥電話 800-596-3440 (TTY: 800-842-5357).

Italiano (Italian):

Oromoo (Cushite):

Français (French):

Deutsche (German):

Hmoob (Hmong):
Este aviso contiene información importante. Puede contener información privada, pero siempre mantendremos su confidencialidad. Si tiene alguna pregunta, por favor llame al Centro de Atención al Cliente de LifeWise Health Plan of Oregon en 800-596-3440. 

Este aviso se aplica a todos los miembros de LifeWise Health Plan of Oregon. Puede contener información importante acerca de su solicitud o cobertura a través de LifeWise Health Plan of Oregon. Por favor, lea este aviso de forma completa antes de tomar cualquier decisión. Si tiene alguna pregunta o necesidad de ayuda, por favor llame al Centro de Atención al Cliente en 800-596-3440.